Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06882174 | This Study is Comparing Morning vs Random Scheduling of Standard of Care Pembrolizumab Checkpoint Inhibitor Immunotherapy Infusions in Patients With Metastatic Non-small Cell Lung Cancer(TIME-NSCLC) | not yet recruiting | Phase 2 | 58 | AHS Cancer Control AlbertaOTHER | 0 | Dec 8, 2025 | clinicaltrials |
| NCT06910761 | Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer | recruiting | Phase 2 | 35 | City of Hope Medical CenterOTHER |
| 1 |
| Dec 8, 2025 |
| clinicaltrials |
| NCT04625647 | Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | active not recruiting | Phase 2 | 116 | SWOG Cancer Research NetworkNETWORK | 2 | Dec 5, 2025 | clinicaltrials |
| NCT05120271 | BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors(DUET-1) | active not recruiting | Phase 1 / Phase 2 | 7 | Sotio Biotech Inc.INDUSTRY | 2 | Dec 5, 2025 | clinicaltrials |
| NCT07256509 | A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 120 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Dec 5, 2025 | clinicaltrials |
| NCT07264647 | Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC) | recruiting | Phase 2 | 30 | Fondazione Ricerca TraslazionaleOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT07070518 | Study of GV20-0251 in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 350 | GV20 TherapeuticsINDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05751018 | Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer | recruiting | Phase 2 | 18 | Peking Union Medical College HospitalOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07259226 | Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers(OASIS) | recruiting | Phase 2 | 400 | UNICANCEROTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07229729 | A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer | recruiting | Phase 2 | 300 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07206498 | A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC(WAYWIN103) | recruiting | Phase 1 / Phase 2 | 48 | Wayshine Biopharm, Inc.INDUSTRY | 1 | Nov 28, 2025 | clinicaltrials |
| NCT04940325 | Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer(ICARUS-LUNG01) | active not recruiting | Phase 2 | 100 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT06107686 | A Study of YL202 in Selected Patients With Advanced Solid Tumors | recruiting | Phase 2 | 200 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07058519 | A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC | recruiting | Phase 2 | 250 | Shanghai Chest HospitalOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT06400160 | Clinical Trial of TB511 in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 12 | Twinpig Biolab, Inc.INDUSTRY | 0 | Nov 25, 2025 | clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06652048 | High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI | recruiting | Phase 2 | 60 | Jialei WangOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT06352008 | To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer | recruiting | Phase 2 | 64 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06496490 | A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality | recruiting | Phase 2 | 270 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06455917 | TIL Therapy in Non-small-cell Lung Cancer (NSCLC) Patients(BaseTIL-02L) | recruiting | Phase 2 | 30 | University Hospital, Basel, SwitzerlandOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT06917573 | PALACE: Cemiplimab Trial According to ctDNA Levels(PALACE) | recruiting | Phase 2 | 63 | Fundación GECPOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT07153445 | Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)(ATHENEA) | recruiting | Phase 2 | 97 | Fundación GECPOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT07235306 | Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC | not yet recruiting | Phase 2 | 45 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Nov 19, 2025 | clinicaltrials |
| NCT05781308 | Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy(ADAPTABLE) | active not recruiting | Phase 2 | 156 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT07175220 | Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects | recruiting | Phase 2 | 200 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 18, 2025 | clinicaltrials |
| NCT07231575 | Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC | not yet recruiting | Phase 2 | 39 | Sun Yat-sen UniversityOTHER | 0 | Nov 18, 2025 | clinicaltrials |
| NCT04180371 | Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | active not recruiting | Phase 1 / Phase 2 | 288 | BicycleTx LimitedINDUSTRY | 5 | Nov 17, 2025 | clinicaltrials |
| NCT05200481 | Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)(MP-ALK) | active not recruiting | Phase 2 | 110 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06542159 | Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer or Pulmonary Oligometastases | recruiting | Phase 2 | 130 | Sun Yat-sen UniversityOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06582940 | Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain Metastasis | recruiting | Phase 2 | 168 | Sun Yat-sen UniversityOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06848699 | A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 105 | Shanghai Henlius BiotechINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT07231068 | A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation | recruiting | Phase 1 / Phase 2 | 153 | Henan Genuine Biotech Co., Ltd.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT05558904 | An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer | recruiting | Phase 1 / Phase 2 | 60 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT04074967 | Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab | active not recruiting | Phase 1 / Phase 2 | 70 | Dan ZandbergOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT03539536 | Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 270 | AbbVieINDUSTRY | 26 | Nov 5, 2025 | clinicaltrials |
| NCT03667820 | Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC | active not recruiting | Phase 2 | 41 | University of Texas Southwestern Medical CenterOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT03334617 | Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy(HUDSON) | active not recruiting | Phase 2 | 528 | AstraZenecaINDUSTRY | 8 | Oct 27, 2025 | clinicaltrials |
| NCT06228326 | A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs(KYANITE-1) | recruiting | Phase 1 / Phase 2 | 250 | Krystal Biotech, Inc.INDUSTRY | 1 | Oct 24, 2025 | clinicaltrials |
| NCT01720836 | Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 30 | Olivera FinnOTHER | 1 | Oct 21, 2025 | clinicaltrials |
| NCT05565417 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | active not recruiting | Phase 1 / Phase 2 | 67 | Immunitas TherapeuticsINDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT00977470 | Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations | active not recruiting | Phase 2 | 76 | Massachusetts General HospitalOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT04931654 | A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer | active not recruiting | Phase 1 / Phase 2 | 136 | AstraZenecaINDUSTRY | 10 | Oct 9, 2025 | clinicaltrials |
| NCT04370587 | A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 30 | ImmVira Pharma Co. LtdINDUSTRY | 2 | Oct 8, 2025 | clinicaltrials |
| NCT05393466 | BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | not yet recruiting | Phase 1 / Phase 2 | 30 | Xcovery Holdings, Inc.INDUSTRY | 0 | Oct 7, 2025 | clinicaltrials |
| NCT06305715 | Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X) | recruiting | Phase 2 | 34 | Medical College of WisconsinOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT05296564 | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers | recruiting | Phase 1 / Phase 2 | 3 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07204548 | The IVO-LUNG Study(IVO Lung) | not yet recruiting | Phase 2 | 63 | Sun Yat-sen UniversityOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07181499 | Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI | recruiting | Phase 2 | 28 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07198217 | Real World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Combined withTislelizumab in Stage IIIB/C-IV Non-small Cell Lung Cancer Patient | recruiting | Phase 2 | 20 | Zibo Municipal HospitalOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07198321 | A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 450 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 1 | Sep 30, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 8, 2025source: clinicaltrials